Sitagliptin onglyza™ (Saxagliptin sitagliptin) is a highly effective dipeptide -4 (dipeptidyl peptidase 4, DPP-4) inhibitor, through selective inhibition of DPP-4, The level of endogenous glucagon-like peptide -1 (Glucagon-like Peptide-1, GLP-1) and glucose-dependent insulin-releasing polypeptide (glucose-dependent insulinotropic peptide, GIP) can be elevated, To regulate blood sugar.
After eating GLP-1 in the intestinal secretion, and then stimulate the pancreas to produce glucose-dependent insulin secretion, while inhibiting glucagon secretion, delayed gastric emptying. In physiological state, DPP-4 can rapidly degrade GLP-1 and GIP, and make it inactive, while taking DPP-4 inhibitor can increase GLP-1 times of endogenous $number level, effectively reduce glycosylated hemoglobin ($literal) and postprandial blood sugar, without affecting weight, without significant hypoglycemia risk. The clinical study of Sitagliptin has been published successively, and it has been confirmed that it reduces the level of $literal, fasting blood sugar (FPG), postprandial blood sugar (PPG) and good tolerability and safety.
In clinical trials, the overall incidence of side effects of onglyza™2 5mg and 5mg was similar to that of placebo 70.6%, respectively, 72%, 72.2%. The most common adverse events in the ONGLYZA™5MG group (≥5% and higher than the placebo group) were upper respiratory tract infections (7 Sandy sitagliptin. 7%, placebo group 7.6%), urinary tract infection (6.8%, placebo group 6.1%) and headache (6.5%, placebo group 5.9%). Of the adult patients with onglyza™2.5mg treatment, only the incidence of headache was ≥5% (6.5%), and more common than the placebo group. Onglyza™2.5mg Group, 5mg Group and placebo group respectively 2.2%, 3.3% and 1.8% patients were discontinued for adverse events. The onglyza™ group observed that the absolute mean value of leukocyte was decreased with dose correlation.
Oral, recommended dose 5mg daily 1 times, the time of taking medicine is not affected by eating. Patients with renal insufficiency: Patients with mild renal insufficiency do not need to adjust the dosage. Patients with moderate to severe renal insufficiency have limited experience in clinical research and are therefore not recommended for this type of patient. (See cautions and pharmacokinetics). Patients with liver dysfunction: mild to moderate liver damage without the need to adjust the dosage (see pharmacokinetics). The use of this product for moderate liver damage should be cautious and not recommended for patients with severe liver damage (see cautions). A potent cytochrome P450 3A4/5 (CYP3A4/5) inhibitor: When combined with potent CYP3A4/5 inhibitors (such as ketoconazole, Atazanavir, clarithromycin, Itraconazole, Nefazodone, Ritonavir, Saquinavir, and doxycycline), the dosage should be limited to 2. $number days. "